Pinealon

Origin and Structure

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR), developed at the St. Petersburg Institute of Bioregulation and Gerontology by the research group led by Vladimir Khavinson. It is one of the shortest peptides in the Khavinson bioregulator family and is positioned as a brain- and pineal-directed short peptide intended to support cognitive function and circadian regulation.

Pinealon is conceptually related to — but structurally distinct from — Epithalon (AGAG), the flagship Khavinson peptide associated with pineal/telomerase work. Epithalon is a tetrapeptide derived from the pineal extract Epithalamin; Pinealon is a shorter, separately optimized tripeptide with a different sequence and a different (though overlapping) claimed activity profile.

Proposed Mechanism

As with other Khavinson peptides, the proposed mechanism is direct transcriptional modulation: short peptides are hypothesized to enter cells, translocate to the nucleus, and bind specific DNA sequences to alter gene expression in tissue-characteristic patterns. For Pinealon, the reported effects in cultured neurons and rodent studies include:

• Reduction of oxidative stress markers and protection of cortical neurons from glutamate excitotoxicity.
• Modulation of serotonergic signaling and melatonin-pathway-adjacent gene expression.
• Attenuation of age-related cognitive decline in rodent aging models.
• Reduction in apoptosis markers after hypoxic insult in hippocampal slice preparations.

Western pharmacology has not independently verified the nuclear-binding model. Alternative mechanisms — receptor-mediated signaling at neuronal membranes, anti-oxidant activity of the side chains, or modulation of proteostasis — cannot be ruled out and may contribute to any genuine biological signal.

Evidence Base

The Pinealon literature is almost exclusively Khavinson-school, published in a mix of Russian-language journals and a smaller set of English translations. Typical studies are small, with limited blinding detail and outcome measures that do not align with international clinical-trial conventions. Independent replication outside the Khavinson group is essentially absent. Western systematic reviews of short peptide bioregulators consistently flag this as the key limitation.

What Pinealon has in its favor is roughly two decades of real-world Russian clinical exposure with few safety signals, which is more than can be said for many peptides that reach the Western research-chemical market.

Practical Considerations

Russian clinical and research protocols typically use 1–10 mg per dose, administered intranasally or by intramuscular injection, for 10–20 day courses that may be repeated seasonally. Intranasal administration is popular in nootropic community use because it avoids injection and plausibly delivers peptide to the CNS via the olfactory pathway. Oral use is not well characterized and is unlikely to be bioavailable for a tripeptide of this composition.

Pinealon is frequently discussed alongside Semax — a different Russian cognitive peptide with a larger evidence base and a clearer BDNF-modulation mechanism — and with Epithalon for those interested in pineal/longevity protocols.

Safety and Regulatory Status

No major safety signals have emerged from Russian clinical use. Reported adverse events are mild: occasional injection-site irritation, transient headache, mild drowsiness. Pinealon is not FDA-, EMA-, or Health-Canada-approved; it is not on the WADA prohibited list. Western availability is limited to research-chemical suppliers, with the usual caveats about purity, identity, and sterile preparation.

The Bottom Line

Pinealon is a minor member of the Khavinson short-peptide family with a plausible but unverified mechanism and a body of evidence that lives almost entirely within a single research lineage. It is safer to interpret Pinealon as a reasonable tolerability candidate within the Russian short-peptide tradition than as a validated nootropic in the sense Western readers might expect. For a more heavily researched cognitive peptide from the same Russian tradition, Semax is the more credible starting point.